{"id":2818,"date":"2026-09-02T09:00:00","date_gmt":"2026-09-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2818"},"modified":"2026-09-01T22:18:38","modified_gmt":"2026-09-02T02:18:38","slug":"preprint-finds-aml-car-t-activity-depends-on-intact-ifn-gamma-signaling","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2818","title":{"rendered":"Preprint Finds AML CAR-T Activity Depends on Intact IFN-Gamma Signaling"},"content":{"rendered":"

Institution:<\/strong> University of Wisconsin-Madison · Mechanism:<\/strong> IFN-gamma Signaling in CAR-T Cytotoxicity · Application:<\/strong> Acute Myeloid Leukemia CAR-T · Stage:<\/strong> Preclinical · Date:<\/strong> August 31, 2026<\/p>\n

\"Preprint<\/p>\n

Summary<\/h4>\n

A non-peer-reviewed study reports that disrupting interferon-gamma signaling impaired anti-AML CAR-T function, unlike the dispensability previously observed in B-cell acute lymphoblastic leukemia models. IFN-gamma increased AML-cell expression of CD123, Fas and ICAM-1 and strengthened CAR-T cytotoxicity and target-cell avidity. The work raises a context-specific caution for using IFN-gamma blockade such as emapalumab to control CAR-T toxicities in AML, but it does not demonstrate worse clinical outcomes or establish a human contraindication.<\/p>\n

What Happened<\/h4>\n

University of Wisconsin-Madison investigators tested pharmacologic and genetic disruption of the IFN-gamma axis in anti-CD123 and other CAR-T systems. In AML models, blockade reduced target-antigen upregulation, apoptotic sensitivity and adhesion needed for stable immune synapse formation. Exogenous IFN-gamma had the opposite effect. Parallel B-ALL systems were less dependent on the pathway, supporting disease-context specificity. The preprint extends an earlier conference abstract with mechanistic experiments. It remains preclinical; the reported evidence does not quantify how clinically used emapalumab exposure, timing or duration affects AML-directed CAR-T expansion, toxicity or remission.<\/p>\n

Deep Analysis<\/h4>\n

If AML blasts rely on IFN-gamma-induced CD123, Fas and ICAM-1 to become efficiently recognized and killed, systemic blockade during peak CAR-T activity could weaken tumor control, and multiple mechanistic nodes support causality rather than simple correlation. Short-course clinical blockade, however, may reduce dangerous inflammation while preserving enough local signaling, and murine or cell-line dependence may not reproduce heterogeneous patient marrow. Baseline or inducible IFN-gamma-response programs could help identify AML cases likely to support CAR-T synapse formation, and engineering strategies might preserve tumor-cell sensitization while decoupling systemic cytokine toxicity, though increasing IFN-gamma signaling could also worsen cytokine-mediated injury, endothelial activation and myelosuppression, limiting the therapeutic window.<\/p>\n

Company and Product Background<\/h4>\n

This is an academic technology signal from the University of Wisconsin-Madison, not a disclosed company program. AML arises from clonal myeloid progenitors in bone marrow and is difficult to target with CAR-T because many candidate antigens, including CD123, are also expressed on normal hematopoietic cells, and myelosuppression, heterogeneous antigen density and an immunosuppressive marrow niche constrain efficacy and safety. CAR-T cells release IFN-gamma after antigen engagement; the cytokine can activate macrophages and endothelium, contributing to inflammatory toxicity, but it also changes tumor-cell antigen presentation, adhesion and apoptotic susceptibility. Emapalumab is an anti-IFN-gamma antibody used in primary hemophagocytic lymphohistiocytosis and explored as a cytokine-toxicity intervention.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Key Finding<\/td>\nIFN-gamma-axis disruption reduced AML CAR-T activity via CD123, Fas, ICAM-1 downregulation<\/td>\n<\/tr>\n
Disease Specificity<\/td>\nAML models dependent on pathway; parallel B-ALL systems less dependent<\/td>\n<\/tr>\n
Clinical Relevance<\/td>\nRaises caution for emapalumab (IFN-gamma blockade) use during AML CAR-T therapy<\/td>\n<\/tr>\n
Validation Status<\/td>\nNon-peer-reviewed preprint; extends earlier conference abstract<\/td>\n<\/tr>\n
Signal Type<\/td>\nPreclinical mechanistic study, safety-management implications<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Multiple mechanistic nodes, CD123, Fas and ICAM-1 upregulation, supported by both blockade and exogenous IFN-gamma experiments, argue for a causal rather than correlative relationship, giving trial designers an actionable variable to test rather than assume as efficacy-neutral.<\/p>\n

Bear case:<\/strong> Murine and cell-line systems may not reproduce heterogeneous patient marrow, and short-course clinical IFN-gamma blockade for toxicity management may preserve enough local signaling to avoid the efficacy cost observed in this preclinical model.<\/p>\n

InSilens Take<\/h4>\n

The paper challenges a simple transfer of toxicity-management logic from B-cell malignancies to AML. Its strongest contribution is mechanistic: IFN-gamma may make AML targets easier to recognize and kill. That is actionable for trial design and correlative sampling, not sufficient to change practice. Clinicians and developers should treat emapalumab timing as a testable exposure variable in AML CAR-T studies rather than assume pathway blockade is efficacy-neutral.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> Moderate-high on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

A non-peer-reviewed study reports that disrupting interferon-gamma signaling impaired anti-AML CAR-T function, unlike the dispensability previously observed in B-cell acute lymphoblastic leukemia models. IFN-gamma increased AML-cell expression of CD123, Fas and ICAM-1 and strengthened…<\/p>\n","protected":false},"author":1,"featured_media":2821,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,507,368],"class_list":["post-2818","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-interferon-gamma","tag-university-of-wisconsin-madison"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2818"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2818\/revisions"}],"predecessor-version":[{"id":2844,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2818\/revisions\/2844"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2821"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}